TVGN - NASDAQ
Tevogen Bio Holdings Inc.
$0.25
-5.8%Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
At a Glance
Live Snapshottvgn
Property, Plant, and Equipment (Net)
Last Annual Value
524.93K
3-Year CAGR
54%
5-Year CAGR
30%
10-Year CAGR
14%
Tevogen Bio Holdings Inc. Competitors Analysis of Property, Plant, and Equipment (Net)
| Company | Property, Plant, and Equipment (Net) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Tevogen Bio Holdings Inc. NASDAQ:TVGN | 524.93K | -17.3% | 29.8% | N/A | |
 Whitehawk Therapeutics Inc NASDAQ:WHWK | 3.00K | -92.1% | -65.5% | N/A | |
 Cognition Therapeutics, Inc. NASDAQ:CGTX | 399.00K | -24.9% | 22.4% | N/A | |
 TuHURA Biosciences, Inc. NASDAQ:HURA | 685.17K | 50.0% | 2.1% | N/A | |
 Instil Bio, Inc. NASDAQ:TIL | 364.00K | -86.3% | -68.7% | N/A | |
 Surrozen, Inc. NASDAQ:SRZN | 6.43M | 18.6% | -7.3% | N/A | |
 Greenwich LifeSciences, Inc. NASDAQ:GLSI | 0.00 | N/A | N/A | N/A | |
 Atossa Therapeutics, Inc. NASDAQ:ATOS | 0.00 | N/A | N/A | N/A | |
 Alto Neuroscience, Inc. NYSE:ANRO | 6.13M | 77.0% | 42.1% | N/A | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 45.28M | -14.0% | 5.3% | N/A | |
 Nuvectis Pharma, Inc. NASDAQ:NVCT | 0.00 | N/A | N/A | N/A |
Tevogen Bio Holdings Inc. Fair Value Envelope
Related Guides
Continue your TVGN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.